Drug intelligence / Profile preview

ID-085

Development stage: Phase 1
Lead developer: Idorsia
Modality: Small Molecules
Administration: Oral

Overview

ID-085 is an investigational oral drug developed by Idorsia Pharmaceuticals (Idorsia Ltd.) for the treatment of urogenital diseases. The specific mechanism of action, molecular target, and detailed pharmacological profile have not been publicly disclosed. As of the latest available information, its highest global R&D status is pending and the primary indication has not been specified beyond a general focus on urogenital diseases.

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on ID-085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ID-085.

Explore the full profile